Views:107 Author:Site Editor Publish Time: 2021-06-10 Origin:Site
Recently, the COVID-19 epidemic in India has been frequently trending. As of June 9, 2021, India has a total of 29,089,069 confirmed cases and a total of 353,528 deaths. In many areas, medical resources are in short supply, such as hospital beds and oxygen, which has brought great challenges to the public health of India and the world.
At present, the SARS-CoV-2 variant B.1.617.2 has become the main local variant strain in some parts of India and has spread to more than 40 countries and regions. The mutated virus mainly carries mutations of L452R and D614G, showing a stronger transmission ability, which brought the attentional challenge to epidemic prevention and control. Currently, the Indian variant B.1.617.2 and the previously popular British variant B.1.1.7 are the main epidemic strains worldwide.
Cope with shifting events by sticking to a fundamental policy
The COVID-19 will keep mutating before the end of the epidemic. As time goes on, the prevalence of various variants is constantly changing. Some variants gradually disappear, yet new virus variants continue to emerge. There are currently 13 important COVID-19 variants, including 8 variants of interest (VOI) and 5 mutants of concern (VOC).
It is worth mentioning that Tianlong's R&D team will follow up the mutation information of the variants as soon as possible in response to the global SARS-CoV-2 mutation situation, and continuously upgrade product performance. Judging from the virus strain sequence analysis and molecular diagnostic product development experience, whether it is the British variant B.1.1.7, the South African variant B.1.351, the Brazilian variant P.1, or the Indian variant B.1.617.2, which all can be tested by Tianlong’s SARS-CoV-2 nucleic acid detection reagents.
Tianlong strength will continue to escort you!
As an innovative leader in the field of nucleic acid detection and molecular diagnostics, Tianlong has strong innovation capabilities, deep technology accumulation, and profound prevention and control experience. SARS-CoV-2 nucleic acid extraction and testing related equipments and reagents have obtained domestic NMPA, EU CE, US FDA and other authoritative registration certifications, and our clients are located in more than 50 countries and regions, contributing "Chinese power" to the world epidemic. No matter how the epidemic situation changes or how variants emerge one after another, we firmly believe that with the efforts of all parties, the epidemic situation will definitely be brought under control as soon as possible!